Delcath Reports Q1 2026 Earnings and Business Update
Delcath (DCTH) reported first-quarter earnings for 2026, with total revenue rising to $25 million from HEPZATO KIT sales. The company noted a net loss of $1.1 million compared to prior-year profits but highlighted strong cash reserves and ongoing share repurchases.
Tickers: $DCTH
Topics: cash_balance gross_margin net_loss patient_starts R&D_expense revenue SG&A_expense